E Keystone

Summary

Affiliation: Mount Sinai Hospital
Country: Canada

Publications

  1. ncbi Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
    Mark C Genovese
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Arthritis Rheum 46:1443-50. 2002
  2. ncbi Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled
    Edward C Keystone
    University of Toronto, Toronto, Ontario M5G 1X5, Canada
    Arthritis Rheum 50:1400-11. 2004
  3. ncbi Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study
    Edward C Keystone
    Mount Sinai Hospital and the University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 39:2238-46. 2012
  4. ncbi Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine
    Edward C Keystone
    The Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases, Mount Sinai Hospital, 60 Murray St, Box 4, Toronto, ON, Canada M5T 3L9
    Ann Rheum Dis 71:1630-5. 2012
  5. ncbi Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial
    Edward C Keystone
    Mount Sinai Hospital, 60 Murray Street, Toronto, ON, Canada
    Rheumatology (Oxford) 51:1628-38. 2012
  6. ncbi Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study
    Edward Clark Keystone
    Rheumatology Department, Mount Sinai Hospital, Toronto, Canada
    Ann Rheum Dis 71:857-61. 2012
  7. ncbi Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study
    Boulos Haraoui
    Department of Rheumatology, CHUM Hopital Notre Dame, Montreal, Quebec, Canada
    BMC Musculoskelet Disord 12:261. 2011
  8. ncbi Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
    Sudha Visvanathan
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    Arthritis Res Ther 12:R211. 2010
  9. ncbi Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
  10. ncbi Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts
    Alison M Connor
    The Wellesley Toronto Arthritis and Immune Disorder Research Centre, 101 College St, Toronto, Ontario, Canada M5G 1L7
    Arthritis Res Ther 8:R94. 2006

Detail Information

Publications58

  1. ncbi Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
    Mark C Genovese
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Arthritis Rheum 46:1443-50. 2002
    ..To compare the clinical and radiographic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy...
  2. ncbi Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled
    Edward C Keystone
    University of Toronto, Toronto, Ontario M5G 1X5, Canada
    Arthritis Rheum 50:1400-11. 2004
    ....
  3. ncbi Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study
    Edward C Keystone
    Mount Sinai Hospital and the University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 39:2238-46. 2012
    ....
  4. ncbi Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine
    Edward C Keystone
    The Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases, Mount Sinai Hospital, 60 Murray St, Box 4, Toronto, ON, Canada M5T 3L9
    Ann Rheum Dis 71:1630-5. 2012
    ....
  5. ncbi Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial
    Edward C Keystone
    Mount Sinai Hospital, 60 Murray Street, Toronto, ON, Canada
    Rheumatology (Oxford) 51:1628-38. 2012
    ..To evaluate the safety and efficacy of 2-year administration of certolizumab pegol (CZP) + MTX in patients with active RA...
  6. ncbi Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study
    Edward Clark Keystone
    Rheumatology Department, Mount Sinai Hospital, Toronto, Canada
    Ann Rheum Dis 71:857-61. 2012
    ..To assess safety, immunogenicity and efficacy in rheumatoid arthritis (RA) patients switched from long-term intravenous to subcutaneous (SC) abatacept...
  7. ncbi Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study
    Boulos Haraoui
    Department of Rheumatology, CHUM Hopital Notre Dame, Montreal, Quebec, Canada
    BMC Musculoskelet Disord 12:261. 2011
    ..This multicenter, open-label, prospective, single cohort study evaluated the effectiveness and safety of adalimumab in a clinical setting reflecting the Canadian standard of care for the treatment of patients with rheumatoid arthritis (RA)...
  8. ncbi Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
    Sudha Visvanathan
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    Arthritis Res Ther 12:R211. 2010
    ..The goal of this study was to identify serum markers that are modulated by treatment with golimumab with or without methotrexate (MTX) and are associated with clinical response...
  9. ncbi Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
    ..The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA)...
  10. ncbi Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts
    Alison M Connor
    The Wellesley Toronto Arthritis and Immune Disorder Research Centre, 101 College St, Toronto, Ontario, Canada M5G 1L7
    Arthritis Res Ther 8:R94. 2006
    ..The results may also partly explain the therapeutic effect of atorvastatin in patients with RA...
  11. ncbi Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial
    Edward C Keystone
    Mount Sinai Hospital, Joseph and Wolf Lebovic Building, Second Floor, Room 2 006, 60 Murray Street, Toronto, Ontario M5G 1X5
    J Rheumatol 38:990-6. 2011
    ..To assess the kinetics of response to certolizumab pegol (CZP), and association between rapid response and longterm outcomes, in patients with active rheumatoid arthritis (RA)...
  12. ncbi Recent concepts in the inhibition of radiographic progression with biologics
    Edward Keystone
    The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Rheumatol 21:231-7. 2009
    ..To provide an update on new concepts in the inhibition of radiographic progression with current and emerging biologic therapy...
  13. ncbi Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA
    Edward Keystone
    Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Toronto, ON M5G 1X5, Canada
    J Rheumatol 36:522-31. 2009
    ..This analysis examined clinical and radiographic responses to methotrexate (MTX), etanercept (ETN), and combination ETN and MTX in patients with moderate versus severe rheumatoid arthritis (RA) in both early and late disease...
  14. ncbi Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    E C Keystone
    University of Toronto and Mount Sinai Hospital, Ontario, Canada
    Ann Rheum Dis 68:789-96. 2009
    ..The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy...
  15. ncbi Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    Edward Keystone
    University of Toronto, Toronto, Ontario, Canada
    Arthritis Rheum 58:3319-29. 2008
    ....
  16. ncbi Switching tumor necrosis factor inhibitors: an opinion
    Edward C Keystone
    University of Toronto, Canada
    Nat Clin Pract Rheumatol 2:576-7. 2006
  17. ncbi Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes
    Edward C Keystone
    University of Toronto, Canada
    Nat Clin Pract Rheumatol 2:594-601. 2006
    ....
  18. ncbi Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy
    E Keystone
    University of Toronto, Toronto, Ontario, Canada
    Arthritis Rheum 59:785-93. 2008
    ..To assess the effects of treatment with rituximab plus methotrexate on patient-reported outcomes in patients with active rheumatoid arthritis (RA) who experienced inadequate response to anti-tumor necrosis factor therapy...
  19. ncbi Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
    E Keystone
    Division of Rheumatology, University of Toronto, Toronto, Canada
    Ann Rheum Dis 68:216-21. 2009
    ..To determine if treatment with a B cell-targeted therapy can inhibit the progression of structural joint damage in patients with rheumatoid arthritis (RA), exhibiting an inadequate response to tumour necrosis factor (TNF) inhibitors...
  20. ncbi B cell targeted therapies
    Edward Keystone
    Department of Medicine, University of Toronto, Ontario, Canada
    Arthritis Res Ther 7:S13-8. 2005
    ..These clinical trial data present promising evidence for B cell targeted therapies as future therapeutic options for RA...
  21. ncbi Clinical implications of understanding radiographic findings in relation to clinical outcomes in rheumatoid arthritis
    Edward C Keystone
    Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, The Joseph and Wolf Lebovic Building, 60 Murray Street, 2nd Floor, Room 2 006, Toronto, Ontario M5T 3L9
    J Rheumatol Suppl 82:11-6. 2009
    ..The apparent dissociation between clinical and radiologic outcomes in patients with RA who are treated with biologic therapies needs to be taken into consideration when evaluating the efficacy of treatment...
  22. ncbi Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
    Edward C Keystone
    Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, Toronto, ON, Canada
    J Rheumatol 38:1234-43. 2011
    ..This review examines the reliability issues related to LTBI diagnostic testing and provides practical direction to help prevent LTBI reactivation and facilitate successful anti-TNF-α treatment...
  23. ncbi Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis
    Edward C Keystone
    Division of Advanced Therapeutics, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, 60 Murray Street, Toronto, Ontario, Canada
    J Rheumatol 38:855-62. 2011
    ..This Year 5 analysis of an open-label extension (OLE) study assessed radiographic progression, clinical efficacy, and safety of adalimumab with concomitant methotrexate (MTX) for patients with active rheumatoid arthritis...
  24. ncbi Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial
    Edward C Keystone
    Mt Sinai Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 50:353-63. 2004
    ..To evaluate the safety, efficacy, and pharmacokinetics of 50 mg etanercept administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA)...
  25. ncbi Abandoned therapies and unpublished trials in rheumatoid arthritis
    Edward C Keystone
    Department of Medicine, University of Toronto, Ontario, Canada
    Curr Opin Rheumatol 15:253-8. 2003
    ..These insights have laid the groundwork for future development of other novel therapeutic agents in the treatment of rheumatoid arthritis...
  26. ncbi Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
    Edward Keystone
    University of Toronto and Mount Sinai Hospital, 60 Murray Street, 2nd Floor, Room 2 006, Toronto, Ontario M5G 1X5, Canada
    Ann Rheum Dis 69:1129-35. 2010
    ..To evaluate the efficacy and safety of golimumab to 52 weeks in patients with active rheumatoid arthritis despite methotrexate...
  27. ncbi Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data
    Edward C Keystone
    Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:1552-62. 2011
    ..Regarding malignancy risk, RCT and observational data are also conflicting; how ever, caution is warranted regarding lymphoproliferative cancers in children and adolescents...
  28. ncbi Safety of biologic therapies--an update
    Edward C Keystone
    Division of Advanced Therapeutics, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital and the University of Toronto, Toronto, Canada
    J Rheumatol Suppl 74:8-12. 2005
    ..Safety issues in concert with efficacy determine risk/benefit ratio and hence a position in the therapeutic algorithm. This brief review focuses on infection, congestive heart, and malignancy...
  29. ncbi Treatments no longer in development for rheumatoid arthritis
    E Keystone
    The Centre for Advanced Therapeutics, Mount Sinai Hospital and University of Toronto, Canada
    Ann Rheum Dis 61:ii43-5. 2002
  30. ncbi Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis
    Edward Keystone
    Mount Sinai Hospital, and University of Toronto, 600 University Avenue, Toronto, Ontario, Canada
    Arthritis Rheum 56:3896-908. 2007
    ..To determine the safety and efficacy of additional courses of rituximab in patients with rheumatoid arthritis (RA)...
  31. ncbi Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis
    Shahin Jamal
    University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada
    Clin Rheumatol 28:413-9. 2009
    ..32) in early disease compared with established disease (2.06). While adalimumab is effective for RA of all disease durations, there is a trend toward superior clinical, functional, and radiographic outcomes in patients with early disease...
  32. ncbi Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
    Michael A Gardam
    Infection Prevention and Control and Tuberculosis Clinic, Division of Infectious Disease, University Health Network, Ontario, Toronto, Canada
    Lancet Infect Dis 3:148-55. 2003
    ..Treatment of latent tuberculosis can be considered on an individual basis for TST-negative patients receiving anti-TNF agents when significant risk factors for infection are present...
  33. ncbi Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up
    Silvia Odorcic
    Faculty of Medicine, University of Toronto, Toronto, Canada
    Cornea 28:89-92. 2009
    ..To report a case of refractory progressive sterile peripheral ulcerative keratitis (PUK) that resulted in late corneal perforation, despite good initial response to tumor necrosis factor-alpha inhibitor infliximab...
  34. ncbi Appropriate and effective rheumatoid arthritis control: role of TNF antagonists
    Edward C Keystone
    Centre for Advanced Therapeutics in Arthritis, Mount Sinai Hospital, and University of Toronto, Toronto, Canada
    Drugs Today (Barc) 39:9-15. 2003
    ....
  35. ncbi Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in canada
    A Russell
    Department of Medicine, University of Alberta Hospital Site, Heritage Medical Research Centre, Edmonton, Canada
    Clin Ther 23:1824-38; discussion 1791. 2001
    ..CONCLUSIONS: With early and aggressive treatment involving new drugs and drug combinations, it may be possible to ameliorate the physical, social, and economic effects of RA...
  36. ncbi Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort
    Veena K Ranganath
    UCLA, Department of Medicine, Division of Rheumatology, Rehabilitation Center, Room 32 59, 1000 Veteran Avenue, Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 66:1633-40. 2007
    ....
  37. ncbi Can tumor necrosis factor inhibitors be safely used in pregnancy?
    Yaser M Ali
    Department of Clinical Immunology and Allergy, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 37:9-17. 2010
    ....
  38. ncbi Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number
    Michael J Wasserman
    Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Division of Advanced Therapeutics, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 31:1912-7. 2004
    ..Reactions were significantly more frequent in infusions where patients were pretreated with the antihistamine diphenhydramine, compared to those not involving pretreatment...
  39. ncbi Therapeutic implications for interferon-alpha in arthritis: a pilot study
    Thomas Wong
    Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
    J Rheumatol 30:934-40. 2003
    ..CONCLUSION: These in vitro data suggest a therapeutic role for IFN-a in the treatment of arthritis through upregulation of critical cytokine antagonists...
  40. ncbi Significance of clinical evaluation of the metacarpophalangeal joint in relation to synovial/bone pathology in rheumatoid and psoriatic arthritis detected by magnetic resonance imaging
    Millicent A Stone
    University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Rheumatol 36:2751-7. 2009
    ..We investigated the reliability and accuracy of physically examining the metacarpophalangeal (MCP) joints to detect inflammatory synovitis using magnetic resonance imaging (MRI) as the gold standard...
  41. ncbi Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy
    Carole L Galligan
    Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
    PLoS ONE 4:e6703. 2009
    ..Immune cell activation is a critical component therefore we examined the cellular activation of peripheral blood mononuclear cells (PBMCs) in the early stages of RA, in order to develop a novel diagnostic modality...
  42. ncbi Comparison of 1.0-T extremity MR and 1.5-T conventional high-field-Strength MR in patients with rheumatoid arthritis
    Ali M Naraghi
    Department of Medical Imaging, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Radiology 251:829-37. 2009
    ..To prospectively determine the comparability of 1.0-T extremity magnetic resonance (MR) imaging and 1.5-T conventional MR for the evaluation of the hand and wrist in assessment of patients with rheumatoid arthritis (RA)...
  43. ncbi CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population
    Erin J Walker
    University of Toronto, Toronto General Hospital, and Mount Sinai Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 60:931-7. 2009
    ..We undertook this study to examine whether CTLA4 and ICOS influence RA and PBC susceptibility by testing CTLA4/ICOS polymorphisms for association with these diseases in Canadian subjects...
  44. ncbi Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study
    Allan Gibofsky
    Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
    Curr Med Res Opin 22:169-83. 2006
    ..RADIUS provides a snapshot of use patterns, effectiveness, and safety of DMARDs, biologics, and combination therapies used to manage RA in clinical practice...
  45. ncbi The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    E William St Clair
    Duke University Medical Center, Durham, NC 27710, USA
    Arthritis Rheum 46:1451-9. 2002
    ..To investigate the relationship between serum concentrations of infliximab, a monoclonal anti-tumor necrosis factor alpha antibody, and clinical improvement from infliximab therapy for rheumatoid arthritis (RA)...
  46. ncbi Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial
    Michael E Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 48:35-45. 2003
    ..To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor alpha antibody, in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite treatment with MTX...
  47. ncbi Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort
    Dinesh Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati and the Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 57:440-7. 2007
    ..To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA)...
  48. ncbi Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Ther 25:1700-21. 2003
    ....
  49. ncbi Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
    ....
  50. ncbi Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study
    Philip J Mease
    Swedish Medical Center, Seattle, Washington, USA
    Arthritis Rheum 54:1638-45. 2006
    ..To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA)...
  51. ncbi Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept
    Boulos Haraoui
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    J Rheumatol 31:2356-9. 2004
    ..To assess the efficacy and monitor serious adverse events in patients with rheumatoid arthritis (RA) switching treatment from infliximab to etanercept...
  52. ncbi Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:3226-35. 2007
    ..To assess whether disease activity levels at treatment initiation or during the first 3 months of therapy predict disease activity at 1 year after treatment initiation...
  53. ncbi Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
    Larry W Moreland
    Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294 7201, USA
    J Rheumatol 33:854-61. 2006
    ..To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug (DMARD) refractory rheumatoid arthritis (RA)...
  54. ncbi What to do with TNF failures
    Edward C Keystone
    Expert Opin Drug Saf 4:149-55. 2005
    ..For patients who fail to respond to TNF inhibitors, a number of promising avenues targeting other aspects of the immune system are under study, and may be brought to the clinic in the near future...
  55. ncbi Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population
    William G Newman
    University of Manchester, Manchester, UK
    Arthritis Rheum 54:3820-7. 2006
    ..The aim of this study was to investigate these associations in a Canadian Caucasian cohort of RA cases and healthy controls...
  56. ncbi Asymmetry of small joint involvement in rheumatoid arthritis: prevalence and tendency towards symmetry over time
    Philippe Zangger
    Hopital Orthopedique de la Suisse Romande, and Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Joint Bone Spine 72:241-7. 2005
    ..To quantify asymmetry of radiological joint damage in rheumatoid arthritis (RA), to determine whether asymmetrical damage to joints in RA becomes symmetrical over time, and to identify factors predictive of symmetrization...
  57. ncbi Tight control for the management of RA--a therapeutic approach worth pursuing
    Edward C Keystone
    Nat Clin Pract Rheumatol 4:57. 2008
  58. ncbi p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis
    Yuji Yamanishi
    Department of Rheumatology, Hiroshima City Hospital, Hiroshima, Japan
    Arthritis Res Ther 7:R12-8. 2005
    ..The determining factor for invasiveness might be proximity to bone or cartilage rather than the presence of a p53 mutation...